Lannett Rolls Out US Adderall XR Rival
Faces Competition From Several Other Approved Generics
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.
You may also be interested in...
Despite reporting a 16.4% drop in turnover in its financial third quarter, Lannett says it has recorded the highest quarterly sales since a key levothyroxine distribution deal fell apart last year. The company has launched 14 products in the financial year so far and plans to launch several more.
Lannett expects soon to launch a generic rival to Adderall XR following FDA approval for its partner SunGen. But the US generics specialist will face considerable competition.
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.